125535

The number primarily refers to a medical research paper titled "Exogenous sickle erythrocytes combined with vascular disruption trigger disseminated tumor vaso-occlusion and lung tumor regression" . Article Overview: JCI Insight 125535

: The study uses "exogenous" (externally introduced) sickle red blood cells in combination with a vascular-disrupting agent to target the blood supply of tumors. 125535

: The treatment demonstrated significant effectiveness in causing lung tumor regression in experimental models. The number primarily refers to a medical research